IS217 Peptide Formulation for Psoriasis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for psoriasis lack effective, stable, and safe formulations that simultaneously target angiogenesis and inflammation, often causing severe side effects and requiring complex combination therapies with increased costs and medical visits.
Innovation Solution
A stable, synthetic decapeptide IS217 is developed, combined with pharmaceutically acceptable excipients, forming anti-angiogenic and anti-inflammatory formulations suitable for subcutaneous, intravenous, or topical administration, which targets VEGFR-2, downregulating p38 kinases and reducing IL-23 and IL-17 secretion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current psoriasis treatments are used, then immune response is targeted, but severe side effects occur and formulation stability is poor
Solution Approach 1:
The treatment approach is segmented into two distinct targeting mechanisms: anti-angiogenic activity against VEGFR-2 and anti-inflammatory activity against inflammatory pathways. This segmentation allows selective inhibition of disease mechanisms while sparing normal physiological functions, thereby reducing side effects while maintaining efficacy
Solution Approach 2:
The formulation uses specific parameter optimization including pH control (pH 6.8 phosphate buffer), temperature control during storage and administration, and concentration optimization of IS217 peptide (1-10 mg/mL) to enhance stability and reduce immunogenicity, thereby reducing side effects
2Adaptability or versatility
If complex combination therapies are used, then multiple targets are addressed, but treatment cost increases and medical visits are required
Solution Approach 1:
The patent combines anti-angiogenic and anti-inflammatory activities into a single pharmaceutical formulation containing the IS217 peptide. This merging of multiple therapeutic functions into one agent simplifies the treatment regimen, eliminating the need for complex combination therapies and multiple medical visits while maintaining multi-target capability
Solution Approach 2:
The IS217 peptide formulation is designed with universal applicability for psoriasis treatment by simultaneously targeting VEGFR-2 mediated angiogenesis and inflammatory pathways. This multi-functional design allows a single agent to address multiple pathogenic mechanisms, reducing therapy complexity
3Reliability
If biologics are used, then treatment efficacy is achieved, but cost is high and stability is compromised
Solution Approach 1:
The patent employs a synthetic peptide (IS217) formulation that is more stable and cost-effective than biologics. The peptide can be synthesized using standard pharmaceutical processes, stored under controlled conditions (2-8°C or -20°C), and administered without the stability issues inherent to biologic products, thereby improving formulation stability while maintaining efficacy
4Productivity
If VEGF inhibitors are used, then angiogenesis is inhibited, but inflammation is not adequately controlled
Solution Approach 1:
The IS217 peptide formulation merges anti-angiogenic and anti-inflammatory activities into a single therapeutic agent. The peptide simultaneously inhibits VEGFR-2 mediated angiogenesis and modulates inflammatory pathways including NF-κB and MAPK signaling, ensuring both angiogenesis inhibition and adequate inflammation control
Solution Approach 2:
The formulation utilizes a composite approach by combining the IS217 peptide with excipients optimized for stability and delivery. This composite formulation ensures both anti-angiogenic and anti-inflammatory activities are delivered effectively, addressing the limitation of pure VEGF inhibitors
Data Source
AI summary
The present invention relates to a stable anti-angiogenic and anti-inflammatory pharmaceutical formulation and pharmaceutical combination for treatment and/or prevention of psoriasis. The present invention also relates to methods of preparation of such formulation and combination and uses thereof.